Table 2:
Multivariate analysis of main outcomes
| GPIIb/IIIa Inhibitor | Cangrelor | Adjusted ORsa | 95% CI | P Value | |
|---|---|---|---|---|---|
| 90-Day mRS 0–2 | 31.5% | 40.0% | 2.22 | 0.42–11.75 | .348 |
| 90-Day mortality | 29.6% | 20.0% | 0.44 | 0.06–3.16 | .411 |
| Any ICH | 37.0% | 26.7% | 0.40 | 0.08–2.09 | .280 |
| Final mTICI 2b–3 | 75.0% | 93.3% | 10.88 | 0.96–123.84 | .054 |
| Final mTICI 2c, 3 | 30.8% | 80.0% | 5.33 | 0.97–29.38 | .055 |
| Final mTICI 3 | 21.2% | 46.7% | 2.77 | 0.59– 13.02 | .198 |
a
Adjusted for age, initial NIHSS score, initial ASPECTS, infarct topography (anterior versus posterior circulation), aspirin administration, and rescue intracranial stent placement.